Redeye comments on Cereno Scientific’s Q4 2022 report. We judge that 2023 has the potential to become a rather eventful year for the company, as we expect several catalysts to potentially have a high and low/medium impact on the share. Furthermore, as the clinical portfolio expands, Cereno Scientific is taking its first steps to evolve towards a more mature company. We make some adjustment to our estimates and valuation.

Länk till analysen